In line with this, two MDM2 inhibitors (MI-319 and MI-219) synergistically augmented anti-tumor effects of therapeutic drug GEM in pancreatic cancer in vitro and in vivo experimental models trough the reactivation of p53 pathway and targeting SIRT1 and Ku70 (183). The gene discussed is SIRT1; the disease is neoplasm.